Literature DB >> 34059242

Newer Therapies in Psoriasis.

Justin W Marson1, Margaret L Snyder2, Mark G Lebwohl2.   

Abstract

Psoriasis is a systemic inflammatory condition that negatively affects the quality of life and medical health of 125 million individuals globally. Although psoriasis has historically been viewed as a skin-limited disease and managed with topical agents (eg, coal tar, corticosteroids, and vitamin D analogues), the recontextualization of psoriasis as a systemic condition involving multiple organ systems has prompted the development of numerous immunomodulating, systemic agents with more targeted mechanisms of action. This article briefly discusses the indications and nuances of new and developing therapeutic agents for psoriasis management.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Aryl hydrocarbon receptor modulator; Biologics; Interleukins; Janus kinase inhibitor; Psoriasis; Therapy; Tumor necrosis factor-alpha; Tyrosine kinase inhibitor

Year:  2021        PMID: 34059242     DOI: 10.1016/j.mcna.2021.04.004

Source DB:  PubMed          Journal:  Med Clin North Am        ISSN: 0025-7125            Impact factor:   5.456


  6 in total

1.  Novel Difluorocyclohexyl Derivatives as IL-17 Modulators for Treating Inflammatory and Autoimmune Diseases.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2022-02-01       Impact factor: 4.345

2.  Novel Difluorocyclohexyl Derivatives as IL-17 Modulators for Treating Inflammatory and Autoimmune Diseases.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-11-18       Impact factor: 4.345

3.  Imidazo[1,2-b]pyridazines as IL-17A Inhibitors for Treating Psoriasis, Rheumatoid Arthritis, and Multiple Sclerosis.

Authors:  Ram W Sabnis
Journal:  ACS Med Chem Lett       Date:  2021-09-13       Impact factor: 4.632

Review 4.  Psoriasis between Autoimmunity and Oxidative Stress: Changes Induced by Different Therapeutic Approaches.

Authors:  Marija V Medovic; Vladimir Lj Jakovljevic; Vladimir I Zivkovic; Nevena S Jeremic; Jovana N Jeremic; Sergey B Bolevich; Ana B Ravic Nikolic; Vesna M Milicic; Ivan M Srejovic
Journal:  Oxid Med Cell Longev       Date:  2022-03-12       Impact factor: 6.543

Review 5.  Role of Yes-Associated Protein in Psoriasis and Skin Tumor Pathogenesis.

Authors:  Jinjing Jia; Yuqian Wang; Xiumei Mo; Dacan Chen
Journal:  J Pers Med       Date:  2022-06-16

6.  Alantolactone Suppresses Proliferation and the Inflammatory Response in Human HaCaT Keratinocytes and Ameliorates Imiquimod-Induced Skin Lesions in a Psoriasis-Like Mouse Model.

Authors:  Wen-Ho Chuo; Yu-Tang Tung; Chao-Liang Wu; Nicole R Bracci; Yu-Kang Chang; Hung-Yi Huang; Chi-Chien Lin
Journal:  Life (Basel)       Date:  2021-06-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.